Treatment of Colorectal Liver Metastases: a Current View

Česká verzia

Authors: M. Oliverius ¹; M. Šafanda ²; L. Petruželka ³
Authors place of work: Klinika transplantační chirurgie IKEM, Praha ¹; Onkologické oddělení Nemocnice na Homolce, Praha ²; Onkologická klinika VFN UK, Praha ³
Published in the journal: Klin Onkol 2010; 23(2): 73-77
Category: Reviews

Summary

Backgrounds:
The Czech Republic has the world’s highest incidence of colorectal cancer, with over 4,500 people dying of this disease each year. It is a well-known fact that up to 50% of patients develop distant metastases.

Methods:
While thanks to novel drugs and the emergence of biological therapy, chemotherapy has been most successful in prolonging patient survival, a complete cure is impossible. Consequently, surgical treatment continues to be the only option potentially capable of achieving complete cure. Advances in surgical management, primarily in reducing morbidity and mortality rates after liver resection, have made it possible to perform surgery on a higher number of patients. Despite this, a large proportion of patients remain in fact primarily inoperable because of the extent of their disease. A combination of individualized surgical and cancer therapy developed by a multidisciplinary team substantially increases the number of patients eligible for radical resection, thus not only improving overall five-year survival rates but, also, significantly extending the symptom-free period.

Aim:
The aim of the paper is to summarize a new perspective of the strategy for treating liver metastases of colorectal cancer and to develop guidelines for new appropriate algorithms.

Key words:
liver metastases – perioperative chemotherapy – adjuvant chemotherapy – liver resection – portal vein embolisation – radiofrequency ablation

Zdroje

1. Nordlinger B, Van Cutsem E, Rougier P et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43(14): 2037– 2045.

2. Adson MA. Resection of liver metastases – when is it worthwhile? World J Surg 1987; 11(4): 511– 520.

3. Scheele J, Stangl R, Altendorf‑ Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77(11): 1241– 1246.

4. Kokudo N, Miki Y, Sugai S et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002; 137(7): 833– 840.

5. de Haas RJ, Wicherts DA, Flores E et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 2008; 248(4): 626– 637.

6. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1 001 consecutive cases. Ann Surg 1999; 230(3): 309– 321.

7. Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1 568 patients. Association Française de Chirurgie. Cancer 1996; 77(7): 1254– 1262.

8. Treska V, Topolcan O, Stanislav K et al. Preoperative tumor markers as prognostic factors of colorectal liver metastases. Hepatogastroenterology 2009; 56(90): 317– 320.

9. Lambert LA, Colacchio TA, Barth RJ Jr. Interval hepatic resection of colorectal liver metastases improves patient selection. Arch Surg 2000; 135(4): 473– 480.

10. Adam R. Colorectal carcinoma with synchronous liver metastases. Br J Surg 2007; 94(2): 129– 131.

11. Weber JC, Bachellier P, Oussoultzoglou E et al. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg 2003; 90(8): 956– 962.

12. Benoist S, Pautrat K, Mitry E et al. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 2005; 92(9): 1155– 1160.

13. Ablorsu E, Kothaj P. Súčasné postavenie chirurgie v liečbe pečeňových metastáz kolorektálneho karcinómu. Klin Onkol 2006; 19(2): 121– 123.

14. Mentha G, Majno PE, Andres A et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of colorectal primary. Br J Surg 2006; 93(7): 872– 878.

15. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23(9): 2038– 2048.

16. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23(9): 2038– 2048.

17. Treska V, Skalický T, Sutnar A et al. Surgical management of the colorectal carcinoma liver metastases. Rozhl Chir 2009; 88(2): 69– 74.

18. Alberts SR. Updated options for liver‑limited metastatic colorectal cancer. Clin Colorectal Cancer 2008; 7 (Suppl 2): S58– S62.

19. Nordlinger B, Sorbye H, Collette L et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri‑ operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. Proc Am Soc Clin Oncol 2007; 25: 962s.

20. Gruenberger B, Scheithauer W, Punzengruber R et al. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal liver metastases. BMC Cancer 2008; 8: 120.

21. Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26(11): 1830– 1835.

22. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6): 649– 655.

23. Adam R, Aloia T, Lévi F et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007; 25(29): 4593– 4602.

24. Rubbia‑ Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin‑based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15(3): 460– 466.

25. Aloia T, Sebagh M, Plasse M et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24(31): 4983– 4990.

26. Younes RN, Rogatko A, Brennan MF. The influence of intraoperative hypotension and perioperative blood transfusion on disease‑free survival in patients with complete resection of colorectal liver metastases. Ann Surg 1991; 214(2): 107– 113.

27. Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regiment predicts steatohepatitis and an increase in 90- day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24(13): 2065– 2072.

28. Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol 2006; 24(31): 4954– 4955.

29. Benoist S, Brouquet A, Penna C et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24(24): 3939– 3945.

30. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long‑term survival. Ann Surg 2004; 240(4): 644– 658.